Growing Body of Evidence Demonstrates the Strong Correlation Between TIR and Diabetes Complications 

HbA1c has been a mainstay for assessing glycemic management for the better part of 40 years, largely due to its robust correlation with diabetic vascular complications as demonstrated in the Diabetes Control and Complications Trial (DCCT). As CGM becomes more firmly established as standard of care, there is now a growing body of literature showing that TIR also is strongly associated with chronic complications. Dr. Roy W. Beck recently reviewed this evidence in light of a post hoc analysis of the DEVOTE trial by Bergenstal et al. Managed care and payer decision makers will find this expert commentary useful as it concisely summarizes the data demonstrating the validity of TIR as a clinical measure in diabetes care.  

Beck RW. The Association of Time in Range and Diabetic Complications: The Evidence Is Strong. Diabetes Technol Ther. 2023;25:375-377. doi: 10.1089/dia.2023.0141.